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Abstract
The histone demethylase lysine-specific demethylase 4A (KDM4A) is reported to be
overexpressed and plays a vital in multiple cancers through controlling gene expression by epigenetic regulation of H3K9 or H3K36 methylation marks. However, the
biological role and mechanism of KDM4A in prostate cancer (PC) remain unclear.
Herein, we reported KDM4A expression was upregulation in phosphatase and tensin homolog knockout mouse prostate tissue. Depletion of KDM4A in PC cells inhibited their proliferation and survival in vivo and vitro. Further studies reveal that
USP1 is a deubiquitinase that regulates KDM4A K48-linked deubiquitin and stability.
Interestingly, we found c-Myc was a key downstream effector of the USP1-KDM4A/
androgen receptor axis in driving PC cell proliferation. Notably, upregulation of
KDM4A expression with high USP1 expression was observed in most prostate tumors and inhibition of USP1 promotes PC cells response to therapeutic agent enzalutamide. Our studies propose USP1 could be an anticancer therapeutic target in PC.
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1 | I NTRO D U C TI O N

2 | M ATE R I A L S A N D M E TH O DS

Prostate cancer is a leading cause of death in American men, behind

2.1 | Cell lines and reagents

only lung cancer. Androgen deprivation therapy is the standardof-care treatment for advanced disease when surgical approaches or
1

HEK293T cells and PC cell lines CWR22RV1 (hereafter named RV1),

radiation fail. Androgen receptor, a member of the steroid hormone

LNCAP, VCAP, LN95, C4-2B, DU145, and PC3 were purchased from

receptor family of ligand-activated nuclear transcription factors,

ATCC. All cell lines were tested and authenticated by karyotyping

plays a key role in PC initiation, progression, and resistance to an-

analysis on 2 June 2018. Expression plasmids containing pCMV-

drogen deprivation therapy. 2-4 Androgen receptor drives PC growth

Flag-KDM4A, pCMV-Flag-USP1, and pCMV-Myc-USP1 were con-

by binding to AREs of target genes and recruiting either coactivators

structed as previously described,18 and pCMV-Myc- USP1 C90S

5

or corepressors. It has yet to be determined which and how AR co-

mutant (a deubiquitinating enzyme activity-disrupted mutant, in

activators regulate AR activity.

which a Cys to Ser point mutation was introduced) was generated

KDM4A (also known as JMJD2A or JHDM3A) reportedly

using a QuikChange Site-Directed Mutagenesis Kit (Stratagene) and

serves as an AR coactivator through H3K9 or H3K36 demeth-

validated by DNA sequencing. The HA-ub plasmid and mutation

ylation at promoters or enhancers of some AR target genes. 6-8

constructs were kindly provided by Professor Jianfei Qi from the

KDM4A also functions in promoting tumorigenesis by impairing

University of Maryland Cancer Center.

DNA damage repair and inducing genomic instability.9 These

KDM4A (C37E5) rabbit mAb #5328, USP1 (D37B4) rabbit mAb

findings suggest KDM4A plays a vital role in development and

#8033, c-Myc (E5Q6W) rabbit mAb #18583, AR (D6F11) XP rabbit

progression of PC. It was recently reported that KDM4A is over-

mAb #5153, di-methyl-histone H3 (Lys9) (D85B4) XP rabbit mAb

expressed in several types of cancer cells, such as breast tu-

#4658, and NKX3.1 (D2Y1A) XP rabbit mAb #83700 were pur-

mors10 and lung cancer.11 However, the regulatory mechanism

chased from Cell Signaling Technology. Anti-ub (sc-8017) Abs were

of KDM4A expression upregulation in cancers remains unknown.

purchased from Santa Cruz Biotechnology. Antibodies against HA

Here, we aim to identify the posttranslational modification con-

(H9658), FLAG (F1804), and β-actin (A1978) were purchased from

trolling KDM4A stabilization and the mechanism of KDM4A in

Sigma. The USP1 inhibitor ML323 was from Selleck Chemicals.

regulating AR activity, which can be exploited for potential ther-

Cycloheximide was purchased from Apexbio.

apeutic interventions.
Deubiquitinating enzymes are proteases that reverse protein
ubiquitination, a process which is significant for normal homeostasis.

2.2 | Cell survival assay

Several DUBs are deregulated in certain types of human cancer and
increasingly being regarded as candidates for drug discovery.12 One

Prostate cancer cells were transfected with the indicated plasmids.

of the best-characterized human DUBs, USP1, is overexpressed in

Cells (1 × 10 4) were plated in 96-well culture plates and cultured

12

The

in RPMI-1640 medium supplemented with 10% FBS. Ninety-

best-characterized function of USP1 is as a regulator of the Fanconi

gastric cancer, melanoma, cervical, sarcoma, and lung cancer.

six-well plates were read in an Epoch2 microplate reader (BioTek

anemia pathway, with USP1-mediated deubiquitination of FANCD2

Instruments). The cell survival ratio was calculated by MTS assay

and FANCI.13-16 In addition to these DNA repair-related functions,

(Promega).

USP1 contributes to preventing bHLH-mediated differentiation,
and thus maintains stem cell characteristics in osteosarcoma cells
by deubiquitinating ID proteins.17 However, the novel substrates

2.3 | Soft agar colony formation assays

and regulators of USP1 in cancers remain largely unclear. Numerous
works are required to characterize the substrates of USP1 and to

Prostate cancer cells were transfected with the indicated plasmids

better understand the mechanisms of USP1 in certain types of

and then 1 × 10 4 cells were plated in 0.25% (w/v) agarose with a

human cancer.

base layer of 0.5% (w/v) agarose. Both layers contained complete

In the present study, we discovered that USP1 regulates cancer

1640 medium. After 2 weeks, colonies were counted by using a light

cell proliferation and response to therapeutic drugs through the

microscope with at 4× magnification with a numerical aperture 0.10

KDM4A/AR-c-Myc pathway. Mechanistically, USP1 deubiquitinated

objective lens (ECLIPSE 80i; Nikon).

and stabilized KDM4A, which promoted recruitment of AR to the
c-Myc gene enhancer. In addition, inhibition of USP1 decreased PC
proliferation and promoted response to therapeutic agent enzalut-

2.4 | Immunoprecipitation

amide in a KDM4A-dependent manner. Notably, KDM4A is upregulated in most prostate tumors from patients, which is positively

Cells were lysed in NETN buffer (50 mmol/L Tris-HCl pH 8.0,

correlated with high expression of USP1, suggesting that KDM4A

150 mmol/L NaCl, 1% NP-40, 1 mmol/L EDTA) with Proteinase

might function as a potential prognostic marker and USP1 could be

Inhibitor Cocktail (MedChemExpress) added before use. The resulting

an anticancer therapeutic target in PC.

lysate was then precleaned using 25 mL protein G Sepharose beads

|
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(GE Healthcare) at 4°C. Immunoprecipitation mixtures, including pro-

deubiquitination assay, 293T cells were transfected with both Flag-

tein lysates, blocked protein G Sepharose, and the indicated Abs or IgG

KDM4A and HA-ub for 2 hours, then treated with 10 μmol/L MG132

control derived from the same species as the indicated Ab, were incu-

for 6 hours. Ubiquitylated KDM4A was purified from the cell ex-

bated on a rotating wheel at 4°C overnight. Sepharose beads with the

tracts with anti-Flag beads and then incubated with the recombinant

bound immunoprecipitates were collected and subjected to 4 washes

GST-USP1-WT or GST-USP1-C90S protein in a deubiquitylation

with the cold NETN buffer and then analyzed by western blot assay.

buffer for 2 hours at 37°C. Reactions were subjected to IB analysis.

2.5 | Chromatin immunoprecipitation

2.8 | Glutathione S-transferase-tagged protein
purification and GST pull-down assays

Prostate cancer cells were cultured in complete RPMI-1640 medium
and infected with lentiviral constructs as indicated in figure legends.

GST-USP1-WT and GST-USP1-C90S in the bacterial expression plas-

Cells were pretreated as described in the figure legends before being

mid pGEX-4T-1 were expressed in the Escherichia coli strain BL21 by

cross-linked with 1% formaldehyde and then sonicated. Soluble chro-

induction with 0.4 mmol/L isopropyl β-d-1-thiogalactopyranoside

matin was immunoprecipitated as described previously.19 Primer

at 16°C and purified with GST beads (Sigma-Aldrich) according to

used for ChIP was c-Myc enhancer 5′-CCAGCGAATTATTCAGAA-3′

the manufacturer’s protocol. For GST pull-down assay, bacterial-

and 5′- AATTACCATTGACTTCCTC-3′. ReChIP analysis was carried

expressed GST or GST-USP1-WT bound to glutathione-Sepharose 4B

19

out as described previously.

Briefly, first-round Ab was added

beads (GE Healthcare) was incubated with Flag-KDM4A expressed in

to chromatin extracts and incubated overnight at 4°C followed

HEK293T cells for 2 hours at 4°C. After reaction, complexes were

by addition of 60 mL salmon sperm/protein A agarose (Upstate

washed at least 4 times with GST-binding buffer, eluted by boiling in

Biotechnology) to recover immunocomplexes. The bound protein

SDS-PAGE loading buffer, and subjected to IB with the indicated Abs.

complexes were eluted by 10 mmol/L DTT at room temperature
for 30 minutes, and the elution was then diluted 10 times with reChIP buffer (1% Triton X-100, 2 mmol/L EDTA, 150 mmol/L NaCl,

2.9 | Immunohistochemistry

20 mmol/L Tris [pH 8.1]) and subsequently reimmunoprecipitated by
addition of the second-round or control IgG Abs overnight at 4°C.

Normal prostate tissue samples and prostate tumor tissue sam-

Recovery and preparation of DNA were carried out, followed by PCR

ples were collected at the Affiliated Cancer Hospital and Institute

using the oligonucleotides described above.

of Guangzhou Medical University. Tissue sample collection was
approved by the Internal Review and Ethics Boards of Guangzhou

2.6 | Protein identification by mass spectrometry

Medical University. Tissue microarray chips containing normal prostate tissue samples and prostate tumor tissue samples were obtained
from Shanghai OUTDO Biotech Co. Immunohistochemical staining

Whole cell lysates from RV1 cells stably expressing Flag-KDM4A

was carried out as described previously. 21 The immunostaining was

were prepared using IP-lysis buffer. Immunoprecipitation of Flag-

blindly scored by 2 pathologists. The IHC score was calculated as

KDM4A was undertaken as described in the figure legend. The

described previously.19 The χ2 test and Pearson’s correlation coef-

precipitated proteins were eluted with 3× Flag peptides. The eluted

ficient were used for statistical analysis of the correlation between

samples were subject to in-solution trypsin digestion, liquid chro-

USP1 and KDM4A expression.

matography-mass spectrometry (MS) analysis and database search
by the proteomic service of Shenzhen University. Identities of the
coprecipitated proteins were determined as described previously. 20

2.7 | In vivo and in vitro deubiquitylation of KDM4A

2.10 | Animal models and mouse xenograft assays
All in vivo studies were undertaken in accordance with the Chinese
Animals (Scientific Procedures) and approved by the Animal Welfare
and Ethical Review Board at Guangzhou Medical University. The

For in vivo KDM4A ubiquitylation assay, cells were transfected with

WT mice and mice with prostate-specific deletion of PTEN (stock

the indicated plasmids, then treated with 20 μmol/L MG132 for

number 006440; Jackson Laboratories) were kindly provided by

8 hours. Cells were collected and lysed in NETN buffer plus 0.1%

Professor Jianfei Qi from the University of Maryland Cancer Center.

SDS, 20 μmol/L MG132, and protease inhibitors. Lysates were in-

All mice were housed under pathogen-free conditions, and killed

cubated with anti-KDM4A Ab for 3 hours and protein A/G agarose

after 3 months were killed when the standard situations occurred.

beads for a further 8 hours at 4°C. The precipitated proteins were

Seven-week-old male BALB/c nude mice were from Charles River

then released from the beads by boiling for 10 minutes in SDS-PAGE

Laboratories in China. A total of 1 × 106 RV1 cells stably expressing

loading buffer and were subjected to IB with the anti-HA-ub Ab. For

plasmids were injected s.c. into male BALB/c nude mice, using the

preparation of ubiquitinated KDM4A as the substrate for the in vitro

standard procedure, by two researchers blinded to the experimental
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F I G U R E 2 KDM4A knockdown inhibits cell proliferation and colony formation in vitro and tumor growth in vivo. A-C, RV1, LNCAP, and
PC3 cells stably expressing control (Ctrl) or KDM4A shRNAs (#1 and #2) were subjected to detection of KDM4A expression. D, Cell viability
after stably expressing control (Ctrl) or KDM4A shRNAs (sh#1 and sh#2) was measured by MTT assay (mean ± SEM of 3 independent
experiments). **P < .01. E, KDM4A knockdown decreased the colony formation by RV1 cells on the cell culture plate. RV1 cells (Ctrl or
KDM4A knockdown) were seeded at low density on the plate, and maintained for 2 wk. Numbers of colonies were counted in 5 high-power
fields (mean ± SEM of 3 independent experiments). **P < .01. F, KDM4A knockdown decreased the colony formation by RV1 cells in soft
agar. RV1 cells (Ctrl or KDM4A knockdown) were grown in sofa agar for 3 wk. Growth conditions and colony number quantification are
as described in (E) (mean ± SEM of 3 independent experiments). **P < .01. G, RV1 cells were transduced with control or KDM4A shRNA
for 24 h. Cells were then maintained in growth media containing 5% charcoal-stripped FBS with or without 1 nmol/L R1881 (synthetic
androgen). Proteins were collected and analyzed by western blot. H, RNAs from (G) were collected and analyzed by quantitative RT-PCR
for selected androgen receptor (AR) target genes (mean ± SEM of 3 independent experiments). *P < .05; **P < .01. I, Indicated RV1 cells
from (G) were seeded at low density on the plate, and maintained for 2 wk. Numbers of colonies were counted in 5 high-power fields
(mean ± SEM of 3 independent experiments). *P < .05; **P < .01. J, Cells from (G) were grown in sofa agar for 3 wk. Growth conditions and
colony number quantification are described in (G). K, L, RV1 cells stably expressing Ctrl or shKDM4A RNAs were injected into BALB/c nude
mice. Tumor images and weights are shown (mean ± SD of 5 mice). All statistical analyses were undertaken with ANOVA. *P < .05; **P < .01.
M, Representative staining of Ki-67 on tumor sections derived from above. Staining was developed by DAB (brown) and counterstained by
hematoxylin (blue). Percentages of Ki-67-positive cells are shown. **P < .01 for Ctrl vs shKDM4A (ANOVA)
groups. Dr Song-Hui Xu and Dr Shu-Zhong Cui, who were completely

the legal mandates and national guidelines for the care and mainte-

blinded to the experimental groups, injected the cells into the mice.

nance of laboratory animals.

After three weeks, we measured the tumors and analyzed the data.
The mice used in these experiments were bred and maintained
under defined conditions at the Animal Experiment Center of the

2.11 | Statistical analysis

College of Medicine (SPF grade), Guangzhou Medical University. The
animal experiments were approved by the Laboratory Animal Ethics

Statistical analysis was carried out using GraphPad software, version

Committee of the Guangzhou Medical University and conformed to

5. Data are presented as the means ± SEM or SD. Student’s t test was

F I G U R E 1 KDM4A expression is elevated in phosphatase and tensin homolog (PTEN) knockout mouse prostate tissue. A, H&E stained
dorsal prostates from 3-mo-old WT and pbsn+ PTEN−/− male mice (PTEN). B, Percentage of Ki-67-positive cells in prostates in (A). **P < .01,
significant difference between genotypes. C, Representative immunohistochemical images of KDM4A expression in WT and PTEN mouse
prostate tissues. D, Transcript levels of selected androgen receptor target genes in the prostates of WT and PTEN mice, RNA for quantitative
RT-PCR was isolated from dorsal prostates of 3-mo-old mice. *P < .05; **P < .01. Data are mean ± SD. E, Representative western blotting
showing indicated protein expression in prostates from WT and PTEN mice (n = 3 mice per genotype)
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applied to assess the statistical significance. P values less than 05

this model, cre-recombinase is under the control of a modified rat

were considered significant. Supplementary materials and methods

prostate-specific probasin promoter (PB-Cre4)22 that drives dele-

are provided in Appendix S1.

tion of the floxed Pten allele in the epithelial cells of the mouse
prostate. Prostate cancer development was monitored in the

3 | R E S U LT S
3.1 | KDM4A expression is elevated in PTEN KO
mouse prostate tissue

PTEN mice at 12 weeks of age, the spontaneous formation of PC
was observed by histopathological analysis (Figure 1A) using Ki67, a marker of cell proliferation. Ki-67 staining was significantly
increased in prostate from the PTEN mice (Figure 1B). To our interest, we found KDM4A protein was significantly increased in the
PTEN mice compared to WT mice (Figure 1C,E), but KDM4A mRNA

To investigate the role of KDM4A in PC, we used the widely char-

level had no change (Figure S1A). It was previously reported that

acterized PTEN KO mouse (hereafter, PTEN mice) model of PC. In

KDM4A interacts with AR and functions as a key AR coactivator

1572
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through its histone demethylase activity. 6 Here, in PTEN mice we

in PC cells and measured the cell proliferation by colony forma-

found a significant increase in transcript levels of some AR tar-

tion assay or soft agar assay. Compared with control cells, KDM4A

get genes (c-Myc, NKX3.1, SPINK3, SLC45A3, FKBP5, and TMPRSS2,

knockdown in the AR-positive RV1 or LNCAP cells decreased cell

but not probasin or SBP), pointing to the possibility that KDM4A

proliferation in the presence or absence of androgen (Figures 2I,J

regulates the expression of a specific subset of AR target genes

and S2E). Of note, the effect of KDM4A knockdown to reduce cell

(Figure 1D). The increase in lesions observed in PTEN-deficient

growth was more apparent under androgen deprivation conditions

mice is not likely to be due to probasin-driven SV40 T-antigen ex-

(Figures 2I,J and S2E).

pression, as the level of probasin transcript protein were similar in

To examine the in vivo protumor activity by KDM4A, control vec-

both WT mice and PTEN mice tissues (Figure 1D). In agreement,

tor or 2 stably expressed shKDM4A cells were individually injected

the dorsal prostates from both genotypes expressed similar tran-

into right s.c. tissues of Balb/c nude mice. Compared with control

script levels of the luminal marker CK8 (Figure 1D), suggesting

cells, KDM4A-knockdown RV1 cells showed a significant reduction

that the reduced expression of AR target genes was not due to a

in tumor size (Figure 2K) and weight (Figure 2L). We next undertook

change in cellular differentiation. Furthermore, we confirmed the

IHC staining for the proliferation marker Ki-67 on xenograft tumor

2 selected AR target genes, c-Myc and NKX3.1, protein expression

sections. KDM4A knockdown reduced the percentage of Ki-67-

are markedly increased in prostate tissue from PTEN mice com-

positive cells (Figure 2M). These results suggest that KDM4A knock-

pared to WT mice (Figures 1E and S1B). These results suggest that

down inhibits proliferation in xenograft prostate tumors, indicating

KDM4A could play an oncogenic role in tumorigenesis in PC, and

that KDM4A participates in PC tumorigenesis.

that may link its role to AR signal.

3.2 | KDM4A knockdown inhibits cell
proliferation and colony formation in intro and tumor
growth in vivo

3.3 | USP1 binds and stabilizes KDM4A
To investigate the mechanism through which KDM4A acts in tumorigenesis, the proteins that interact with KDM4A were identified and
USP1, a deubiquitinase, was one of the top-scored proteins identi-

Given the abnormal expression of KDM4A in PTEN mice, we then

fied by MS analysis (Figure 3A) (MS data available upon request). The

assessed whether KDM4A knockdown affects PC cell growth in

interaction between KDM4A and USP1 was confirmed by coimmu-

vitro. We knocked down KDM4A expression in two AR-positive

noprecipitation experiments in 293T cells overexpressing KDM4A

PC cells (RV1 and LNCAP) and one AR-negative PC3 cell line.

(Figure 3B). To determine whether KDM4A and USP1 directly inter-

Separately, both constructs reduced mRNA levels (Figure S2A)

act, we mixed the purified GST-USP1 with the purified Flag-KDM4A

and expression of KDM4A protein (Figure 2A-C). Further evaluat-

and tested the in vitro binding between the 2 proteins. GST- USP1,

ing the role of KDM4A in PC proliferation, we found that PC cell

but not GST protein, was coprecipitated with Flag-KDM4A, indi-

proliferation was obviously decreased when KDM4A was knocked

cating a direct interaction between the 2 proteins (Figure S3A).

down in AR-positive PC cells (Figures 2D and S2B), but partially

Furthermore, immunofluorescence staining revealed that endog-

reduced AR-negative PC3 cells, suggesting that KDM4A might

enous KDM4A and USP1 were mainly colocalized in punctate struc-

require AR to regulate cell proliferation. Concordantly, KDM4A

tures spreading throughout the nucleus (Figure 3C).

knockdown also decreased the number and size of cell colonies

Multiple reports showed WDR48 act as a strong activator of

in RV1 (Figure 2E) and LNCAP cells (Figure S2C). Consistent with

USP1 by enhancing the USP1-mediated deubiquitination. 23,24

this result, as determined in RV1 cells by soft agar colony forma-

To test whether WDR48 is required for the interaction between

tion assays (Figure 2F). To determine whether KDM4A regulates

KDM4A and USP1, we undertook coimmunoprecipitation exper-

AR activity in human PC cells, KDM4A-knockdown RV1 cells were

iments in RV1 cells using KDM4A or WDR48 Ab pull-down as-

cultured in medium supplemented with 5% charcoal-stripped

says. As shown in Figure 3D,E, the interaction between KDM4A

(CS)-FBS (which has low androgen levels) for 2 days then stimu-

and WDR48 was confirmed by reciprocal coimmunoprecipitation

lated with the synthetic androgen R1881 (to restore androgens

experiments. In addition, the association of endogenous KDM4A

to physiological levels) for 24 hours. We found that protein levels

with USP1 was reduced by WDR48 knockdown treatment in RV1

of KDM4A were not affected irrespective of the androgen condi-

cells (Figure 3F). As is well known, active transcription foci are

tions, but AR protein levels were slightly increased in both RV1 and

distributed in the nucleus in a punctate pattern; therefore, USP1,

LNCAP cells after R1881 treatment (Figures 2G and S2D). KDM4A

WDR48, KDM4A, and AR might form a complex to regulate tran-

knockdown has no effect on AR protein levels irrespective of the

scription in PC cells.

androgen conditions (Figures 2G and S2D). Furthermore, quantita-

The interaction of USP1 and KDM4A led us to test a potential

tive RT-PCR analysis showed that KDM4A knockdown in RV1 cells

role for the ubiquitination enzyme USP1 in the regulation of KDM4A

reduced mRNA levels of the selected AR target genes under either

turnover and function. USP1 knockdown in RV1, LNCAP, and PC3

androgen-deprived or normal conditions (Figure 2H). To further

cells significantly decreased KDM4A protein level (Figure 3G), but

determine the role of KDM4A in PC, we knocked down KDM4A

did not affect KDM4A mRNA level (Figure S3B). In addition, treating

|
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cells with the proteasome inhibitor MG132 did not significantly re-

regulate c-Myc expression at both transcriptional and posttran-

duce KDM4A protein level in cells with downregulation of USP1

scriptional levels. We previously found that USP1 knockdown

(Figure 3H). Furthermore, overexpression of WT USP1 but not the

decreased levels of KDM4A in PC cells. To evaluate the possible

catalytic inactive mutant (CS mutant) in RV1 cells could dramatically

involvement of the USP1-KDM4A axis in modulating c-Myc ex-

increase KDM4A protein level in the cells with depletion of USP1

pression. We test whether KDM4A was able to rescue the effect

(Figure 3I). We then hypothesized that USP1 might regulate KDM4A

caused by USP1 depletion. As shown in Figure 5C, USP1 knock-

stability. As shown in Figure 3J, KDM4A protein was more stable

down dramatically reduced levels of KDM4A and c-Myc, whereas

after overexpression of USP1. Taken together, these results suggest

the reconstitution of KDM4A was able to efficiently rescue their

that USP1 directly regulates KDM4A stability.

expression. In addition, our qPCR analysis also showed that USP1
knockdown in AR-positive PC cells decreased c-Myc mRNA levels, whereas the reconstitution of KDM4A was able to efficiently

3.4 | USP1 deubiquitinates KDM4A

rescue the effect (Figure 5D). To examine whether expression of
c-Myc could rescue the effect of USP1 and KDM4A depletion on

To further investigate whether USP1 functions as a deubiqui-

proliferation and survival of PC cells, we undertook MTT assay.

tin ligase for KDM4A, we undertook a deubiquitination assay by

We found reconstitution of c-Myc was able to efficiently increase

cotransfecting cells with WT USP1 or the CS mutant in the pres-

the proliferation and survival of the RV1 cells with depletion of

ence of MG132. A significant decrease in polyubiquitylated KDM4A

USP1 or KDM4A (Figure S4B). Taken together, these results indi-

protein was observed in cells transfected with WT USP1, whereas

cate that USP1 promotes the expression of c-Myc by regulating

the expression of CS mutant was not able to significantly reduce

KDM4A. We next asked how the USP1-KDM4A axis increases AR-

KDM4A ubiquitination (Figure 4A). Conversely, using 2 different

dependent c-Myc transcription. As KDM4A is a coactivator of AR, 6

shRNAs of USP1 dramatically increased KDM4A ubiquitination

and the c-Myc gene enhancer contains an ARE, 26 we undertook a

(Figure 4B). Notably, the USP1 inhibitor, ML323,

25

significantly in-

ChIP assay using a KDM4A Ab to determine whether KDM4A as-

creased KDM4A ubiquitination (Figure 4C). To determine whether

sociates with the ARE on the c-Myc enhancer. We found silenc-

USP1 functions as a direct deubiquitinase for KDM4A, ubiqui-

ing of either USP1, KDM4A, and/or AR reduced KDM4A binding

tinated KDM4A was incubated with purified GST fusion USP1

to c-Myc the enhancer (Figure 5E). To evaluate whether KDM4A

(WT) or USP1 (CS) in vitro. As shown in Figure 4D. A significant

regulates AR binding to the c-Myc enhancer, we undertook an

decrease in polyubiquitylated KDM4A protein was observed in

AR ChIP assay. Downregulation of either USP1, KDM4A, and/or

cells transfected with GST fusion USP1, whereas GST fusion USP1

AR decreased binding of AR to the c-Myc enhancer (Figure 5F).

(CS) was not able to reduce KDM4A ubiquitination. Furthermore,

Consistent with the role of KDM4A as the H3K9me2 demethyl-

we found that USP1 overexpression decreased the polyubiquitina-

ase, downregulation of either USP1, KDM4A, and/or AR increased

tion levels in WT, K6R, K11R, K27R, K29R, K33R, and K63R HA-

levels of the H3K9me2 mark at the c-Myc enhancers (Figure 5G).

ubiquitin mutants but not in K48R mutant (Figure 4E), suggesting

To determine whether the USP1-KDM4A axis-dependent tran-

USP1 promotes KDM4A K48-linked deubiquitin; however, which

scription of c-Myc requires the AR ligand, we maintained the PC

E3 ubiquitin ligase mediated KDM4A ubiquitin and degradation is

cells (control, shUSP1, and shUSP1 + KDM4A) in the media sup-

still unclear. Taken together, these results suggest USP1 is a new

plemented with CS FBS that contains extremely low levels of an-

deubiquitinase that regulates KDM4A K48-linked deubiquitin and

drogen for 2 days, followed by treatment of cells with or without

stability.

synthetic androgen R1881 for 1 day. We found that R1881 induced
a significant increase in NKX3.1 (a positive control) transcript in

3.5 | c-Myc is a downstream effector of USP1KDM4A axis in PC cells

RV1 cells, but it failed to induce the c-Myc transcript, and USP1
knockdown reduced the c-Myc or NKX3.1 transcript similarly,
with or without R1881. However, the reconstitution of KDM4A
was able to efficiently rescue the effect (Figure 5H). These re-

Because of the key role of c-Myc in PC and our above findings that

sults suggest that AR ligand is not required for USP1- KDM4A

KDM4A regulates c-Myc transcription, we determined whether

axis-dependent transcription of c-Myc. To further confirm this re-

c-Myc is a downstream effector of KDM4A. We knocked down

sult, we undertook ChIP assay using AR Ab in RV1 cells (control,

KDM4A in 2 AR-positive PC cells (RV1 and LNCAP) and two AR-

shUSP1, and shUSP1 + KDM4A). Even in the absence of R1881,

negative cells (PC3 and DU145). KDM4A knockdown in the 2 AR-

we observed the binding of AR to the c-Myc gene enhancer in RV1

positive PC cells (RV1 and LNCAP) significantly decreased mRNA

control cells (control), and such binding was not affected by treat-

levels of c-Myc, whereas it had no effect in the 2 AR-negative PC

ment with R1881 (Figure 5I). Knockdown of USP1 equally reduced

cells (PC3 or DU145) (Figure 5A). Furthermore, western blot analy-

the binding between AR and c-Myc enhancer in the presence or

sis showed that downregulation of c-Myc expression, but not AR,

absence of R1881, and the reconstitution of KDM4A partially res-

following KDM4A knockdown in 2 AR-positive (Figure 5B) or in

cued the effect (Figure 5I), suggesting that USP1 not only regu-

AR-negative PC cells (Figure S4A), suggesting that KDM4A might

lates the binding between AR and c-Myc enhancer by KDM4A, but

1574

|

CUI et al.

F I G U R E 3 USP1 binds and stabilizes KDM4A. A, Proteins that interacted with KDM4A were identified by Co-IP and mass spectrometry
assays. B, RV1 cells were transfected with Flag-KDM4A plasmids for 48 h, and lysates were subjected to immunoprecipitation with antiKDM4A Ab. Bound proteins were analyzed by western blotting with anti-KDM4A or USP1 Abs. C, Representative fluorescence images
of KDM4A and USP1 proteins in RV1 cells. Cells were seeded on coverslips for 24 h and then stained for KDM4A (red) and USP1 (green).
Nuclei were visualized by DAPI staining (blue). D, E, RV1 cells were lysed and immunoprecipitated (IP) with indicated Abs. Immunocomplexes
were subjected to western blotting. F, RV1 cells stably expressing control or WDR48 shRNAs were lysed and IPed with indicated Abs.
Immunocomplexes were subjected to western blotting. G, RV1 cells stably expressing control or USP1 shRNAs were subjected to western
blotting to examine the indicated proteins. H, Cells were untreated or treated with 10 μmol/L MG-132 and western blotting was carried
out to examine the indicated protein levels. I, 293T cells were transfected with indicated constructs. Indicated proteins were analyzed by
western blotting. J, RV1 cells were stably expressed control or Flag-USP1 constructs and then cycloheximide (CHX) pulse-chase assay was
undertaken in cells. Right panel, protein levels of USP1 relative to β-actin
also by other transcription factors. Conversely, a low level of AR

absence of androgen. This result is consistent with the previous

was associated with NKX3.1 enhancer in the absence of R1881,

report that AR upregulates the expression of c-Myc in a ligand-

whereas after R1881 treatment, the binding of AR to NKX3.1 en-

independent manner. 5

hancer was highly enhanced (Figure 5I). Taken together, our results

To further test the role of USP1 in KDM4A-dependent tumor

reveal that the USP1-KDM4A axis is required for the constitutive

growth in vivo, we used a xenograft prostate tumor model in

association between AR and c-Myc enhancer in the presence or

which RV1 cells were injected into nude mice. Compared with

|
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F I G U R E 4 USP1 deubiquitinates KDM4A. A, 293T cells were transfected with Flag-KDM4A, Myc-USP1, and HA-tagged ubiquitin (HAub) as indicated. Cellular lysates were coimmunoprecipitated by anti-Flag Ab. Polyubiquitylated KDM4A protein was detected by anti-HA-ub
Ab. B, RV1 cells stably expressing control or USP1 shRNAs were subjected to ubiquitination assay and the polyubiquitylated KDM4A protein
was detected by anti-ub Ab. C, RV1 cells transfected with Flag-KDM4A were treated with or without 10 μmol/L ML323 (USP1 inhibitor).
Polyubiquitylated KDM4A protein was examined as in (B). D, Deubiquitination of KDM4A in vitro by USP1. Ubiquitinated KDM4A was
incubated with purified GST fusion USP1 (WT) or USP39 (CS) in vitro and then blotted with indicated Abs. E, 293T cells were transfected
with Myc-USP1, Flag-KDM4A, and HA-ub (WT, K6R mutant, K11 mutant, K27 mutant, K29 mutant, K33 mutant, K48 mutant, and K63
mutant). Analysis was carried out as described in (A)

control cells, USP1 knockdown cells showed a significant decrease

percentage of Ki-67-positive cells, whereas the reconstitution of

in tumor size (Figure 5J) and weight (Figure 5K) whereas the recon-

KDM4A in USP1 knockdown cells could significantly rescue the

stitution of KDM4A in USP1 knockdown cells could significantly

effect (Figure 5L).

rescue xenograft tumor formation (Figure 5J,K). In addition, we

Overall, these findings revealed that c-Myc was a key down-

carried out IHC staining for the proliferation marker Ki-67 on xe-

stream effector of the USP1-KDM4A axis to drive the growth and

nograft tumor sections (Figure 5L). USP1 knockdown reduced the

survival of PC cells.
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F I G U R E 5 c-Myc is a downstream effector of the USP1-KDM4A axis in androgen receptor (AR)-positive cells. A, c-Myc mRNA levels
were detected in AR-positive cells (RV1 and LNCAP) and AR-negative cells (PC3 and DU145) stably expressing control (Ctrl) or KDM4A
shRNAs (#1 and #2). **P < .01. B, Western blotting of AR-positive cells (RV1 and LNCAP) to examine the indicated proteins. C, RV1 cells
stably expressing control (Ctrl) or USP1 shRNAs with or without Flag-KDM4A were analyzed by western blot. D, c-Myc mRNA levels were
detected in indicated cells stably expressing Ctrl or USP1 shRNAs with or without Flag-KDM4A. *P < .05; **P < .01. E, RV1 cells were
transduced with USP1, KDM4A, or AR shRNAs for 48 h and subjected to ChIP assay using anti-KDM4A Ab. Chromatin was analyzed by
quantitative PCR (qPCR) for regions of the c-Myc enhancer showing an androgen-responsive element (ARE). Knockdown (KD) of USP1,
KDM4A, or AR decreased KDM4A binding to ARE region. *P < .05; **P < .01. F, Cells as described in (E) were subjected to ChIP assay using
anti-AR Ab. Chromatin was analyzed by qPCR for regions of the c-Myc enhancer showing an ARE. KD of USP1, KDM4A, or AR decreased
AR binding to ARE region. *P < .05; **P < .01. G, Cells as described in (F) were subjected to ChIP assay using anti-H3K9Me2 Ab. KD of USP1,
KDM4A, or AR decreased H3K9Me2 binding to ARE region. *P < .05; **P < .01. H, RV1 cells stably expressing Ctrl or USP1 shRNAs with or
without Flag-KDM4A were maintained in growth media containing 5% charcoal-stripped FBS with or without 1 nmol/L R1881 for 48 h, then
c-Myc and NKX3.1 mRNA levels were detected. *P < .05; **P < .01. I, Cells as described in (H) were subjected to ChIP assay by anti-AR Ab.
Chromatin was analyzed by qPCR for regions of the c-Myc enhancer and NKX3.1 enhancer showing AREs. J, K, RV1 cells stably expressing
Ctrl or shUSP1 RNAs were injected into BALB/c nude mice. Tumor images and weights are shown (mean ± SD of 5 mice). All statistical
analyses were undertaken with ANOVA. *P < .05; **P < .01. L, Representative staining of Ki-67 on tumor sections derived from above.
Staining by DAB (brown) and counterstained by hematoxylin (blue). Percentages of Ki-67-positive cells are shown. **P < .01 (ANOVA)
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USP1 expression in clinical PC samples
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we undertook IHC staining of KDM4A and USP1 in PC tissue microarrays (Figure 6C). Notably, upregulation of KDM4A expression
and high USP1 expression were observed in 70% (102 of 146) and

Previous studies have reported that KDM4A upregulation has been

75% (109 of 146) of prostate tumors, whereas only 23% (8 of 35)

observed in PC.9,27,28 As KDM4A plays a key role in human cancer

and 26% (9 of 35) of normal prostate tissues showed high KDM4A

development, it is possible that in human cancers USP1 promotes the

expression and upregulation of USP1 expression, respectively

deubiquitination and stabilization of KDM4A. To determine the rel-

(Figure 6D). To our excitement, a significant positive correlation

evance of regulation of KDM4A/AR-c-Myc signaling by USP1 in pa-

(R = 0.405, P < .001) between the KDM4A and USP1 protein levels

tients, we undertook IHC staining of KDM4A and USP1 on PC tissue

was observed in these prostate tumors: 74.5% (76 of 102) of tumors

microarrays. First, we detected the expression of USP1 and KDM4A

with high KDM4A expression also displayed upregulation of USP1

in PC cell lines and cancer tissue samples. As shown in Figure 6A,

expression (Figure 6D). However, it should be noted that 25.5% (26

USP1 protein levels were positively correlated with KDM4A expres-

of 102) of all tumor specimens had high KDM4A expression but low

sion in AR-positive and AR-negative PC cells. Furthermore, west-

USP1 expression (Figure 6D). Taken together, these results reveal

ern blot analysis showed high USP1 protein levels correlated with

that upregulation of USP1 expression could contribute to KDM4A

increased KDM4A expression in most PC samples (Figure 6B). To

overexpression in a substantial fraction of human prostate tumors,

determine the relevance of KDM4A regulation by USP1 in patients,

whereas in other prostate tumors, KDM4A can be activated by other

F I G U R E 6 KDM4A expression positively correlates with USP1 expression in clinical prostate cancer (PC) samples. A, Expression of USP1
and KDM4A in androgen receptor (AR)-positive (RV1, C42B, LNCAP, VCAP, and LN95) and AR-negative cells (PC3 and DU145) was analyzed
by western blot. B, A subset of prostate tumor (T) and normal tissues (N) were subjected to western blotting, to examine USP1 and KDM4A
protein levels. C, Representative staining of USP1 and KDM4A in PC and normal prostate tissues. D, Quantification of USP1 and KDM4A
protein levels in normal and PC tissues, and the correlation study of USP1 and KDM4A expression level in prostate carcinoma. Statistical
analyses were undertaken with the χ2 test, P < .001. R, Pearson’s correlation coefficient
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F I G U R E 7 Targeting USP1 promotes prostate cancer cells’ response to therapeutic agent enzalutamide. A, RV1 (left panel) or LNCAP
(right panel) cells were treated with the indicated concentrations of ML323 for 48 hours and analyzed by western blotting for the indicated
proteins. B, RV1 or LNCAP cells were treated with 5μmol/L ML323 for 48 h and mRNA levels of the indicated genes were detected
(mean ± SEM of 3 independent experiments). *P < .05; **P < .01. C, RV1 cells were seeded at low density on the plate, and maintained for
2 wk. Numbers of colonies were counted in 5 high-power fields (mean ± SEM of 3 independent experiments). **P < .01. D, RV1 cells were
stably expressed with or without Flag-KDM4A constructs and treated with either vehicle or USP1 inhibitor ML323 for 24 h. Cells were
subjected to western blot to examine the indicated protein levels. E, Cells as described in (D) were treated with the indicated concentrations
of enzalutamide and cell survival was determined (mean ± SD [n = 3]). F, RV1 cells stably expressing control (Ctrl) or USP1 shRNA with or
without Flag-KDM4A were subjected to western blotting to detect the indicated protein levels. G, Cells as described in (F) were treated
with the indicated concentrations of enzalutamide and cell survival was determined (mean ± SD [n = 3]). H, Schematic representation of how
USP1 regulates androgen receptor (AR) and c-Myc activities through KDM4A

posttranslational regulation, eg downregulation of microRNA-10

reveal that targeting USP1 promotes PC cell response to therapeutic

was correlated with high expression levels of KMD4A in human

agent enzalutamide. In future, the combination of USP1 inhibitor and

prostate tumors.

29

enzalutamide should be tested in vivo. Collectively, we showed that
USP1 interacts with KDM4A and promotes its deubiquitination, ulti-

3.7 | Targeting USP1 promotes PC cell response
to therapeutic agent enzalutamide
Our above findings suggest that targeting the USP1-KDM4A axis
could antagonize the growth of PC cells. Although specific KDM4A

mately leading to KDM4A stabilization, and inhibition of USP1 promotes the response of PC cells to therapeutic agent enzalutamide
(Figure 7H).

4 | D I S CU S S I O N

inhibitors are not available, a special selective USP1 inhibitor, ML323,
has been developed. 25 We asked whether ML323 could be used to

Our study found that KDM4A is required to support increased cel-

target the KDM4A stability. We found that ML323 treatment of 2

lular proliferation and cell survival in PTEN prostate tissue. USP1 is

AR-positive cell lines (RV1 and LNCAP) and 1 AR-negative cell line

a deubiquitinase that regulates KDM4A K48-linked deubiquitin and

(PC3) led to the downregulation of KDM4A protein levels in a dose-

stability. In addition, we found that c-Myc serves as a key down-

dependent manner and the reduced KDM4A levels were accom-

stream effector of the USP1-KDM4A/AR axis in driving PC cell

panied by reduced levels of the KDM4A downstream target c-Myc

proliferation as well as survival. These results suggest that KDM4A

(Figures 7A and S5A). Moreover, qPCR data analysis showed that

might function as a potential prognostic marker and USP1 could be

treatment of RV1 or LNCAP cells with 5 μM ML323 reduced c-Myc

an anticancer therapeutic target in PC.

mRNA levels, but not others (Figures 7B and S5B); c-Myc mRNA lev-

KDM4A is upregulated in various cancers including lung, breast,

els were not decreased in AR-negative PC3 cells (Figure S5B). These

colon, and PC and its expression is vital for cell survival.10-11,32-36

results indicated that USP1 inhibitor ML323 can destabilize KDM4A

Here, we found that KDM4A is overexpressed in PTEN KO mouse

protein. To test the effect of ML323 on PC cell growth, we treated

prostate tissue and human prostate tumors, which supports that

RV1 and LNCAP cells with different doses of ML323 and undertook

KDM4A drives PC progression. Moreover, we showed that KDM4A

colony formation assays. As shown in Figures 7C and S5C, inhibition

knockdown decreased cell proliferation in vitro and in vivo. These

of USP1 led to decreased colony formation.

results provide supportive evidence for KDM4A as a potential
6

KDM4A regulates AR activity as an AR coactivator and the sec-

therapeutic target in PC. KDM4A reportedly serves as an AR co-

ond new-generation AR pathway inhibitor enzalutamide extends

activator and regulates gene expression through H3K9 and H3K36

patient life by only a few months.30,31 Thus, we tested whether in-

demethylation.6-8 Consistent with previous findings that KDM4A is

hibition of USP1 by its pharmacological inhibitor or specific shRNA

an AR coactivator and AR upregulates c-Myc mRNA independent of

affects cell response to enzalutamide. RV1 and LNCAP cells were

its ligand in PC cells, we found that KDM4A can recruit AR to the

treated with vehicle or 5 μmol/L USP1 inhibitor and then responses

c-Myc enhancer and demethylate H3K9me2 at that locus, whereas

to enzalutamide were subsequently measured. We observed that the

androgen is not required for the KDM4A-dependent binding of AR

USP1 inhibitor promoted KDM4A degradation (Figure 7D). ML323

to c-Myc enhancer.

sensitized cells to enzalutamide treatment, whereas overexpression

Whether the KDM4A/AR-c-Myc pathway can be regulated in

of KDM4A in the cells was significantly resistant to enzalutamide

PC remains an unanswered question. Identifying new upstream ef-

treatment even in the presence of ML323 (Figures 7E and S5D).

fectors of this pathway could contribute to improved understanding

Similarly, USP1 knockdown in RV1 cells using 2 specific shRNAs sig-

of the molecular events involved in PC progression and clarify new

nificantly decreased KDM4A protein levels (Figure 7F) and increased

potential therapeutic targets in PC. Herein, by performing tandem

cellular sensitivity to enzalutamide treatment, whereas overexpres-

affinity purification, we identified that the KDM4A binding pro-

sion of KDM4A in depleted cells with USP1 reversed hypersensitiv-

tein, USP1, functions as a deubiquitinase and stabilizes KDM4A,

ity to enzalutamide treatment (Figures 7G and S5E). These results

which in turn facilitates AR recruitment to the c-Myc enhancer.
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Thus, our study identified a new player in the AR signaling pathway.

In summary, this study identifies USP1 as a critical deubiquiti-

Furthermore, we found that USP1 knockdown reduced tumorigen-

nase for stabilizing KDM4A, thereby promoting PC growth and

esis and promoted PC cell response to therapeutic agent enzalut-

tumorigenesis. Anticancer effects of USP1 inhibition could be par-

amide in a KDM4A-dependent manner. The supportive evidence is as

tially reversed by overexpression of KDM4A in vitro and in vivo.

follows: (i) USP1 knockdown decreased PC cell proliferation in vitro

Interestingly, USP1 was positively correlated with KDM4A protein

and tumorigenesis in vivo, and promoted the response to therapeutic

expression in prostate human tumors. Combination treatment of en-

agent enzalutamide; and (ii) inhibition of USP1 sensitized cancer cells

zalutamide and targeting KDM4A stabilization through pharmaco-

to therapeutic agent enzalutamide, whereas this effect was blunted

logical inhibition of USP1 by ML323 could thus open an avenue for

by overexpression of KDM4A. Collectively, our study indicates that

therapeutic intervention in PC patients.

USP1 is a new upstream effector of the KDM4A/AR-c-Myc pathway
in PC. To our interest, USP1 reportedly destroys K63-linked poly-
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ubiquitin chains on histones and then promotes to recruit 53BP1 at
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why the activity of KDM4A is tightly regulated under physiological
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